Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fallopian Tube Neoplasms 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Breast Neoplasms 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

entinostat 1Pharmacogenomic Testing 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Anatomic Stage III Breast Cancer AJCC v8 × Pharmacogenomic Testing × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡